ImaginAb, MacroGenics Ink Deal for Companion Molecular Imaging Agents | GenomeWeb

NEW YORK (GenomeWeb News) – ImaginAb, a Los Angeles-based developer of molecular imaging agents, has entered into an alliance with MacroGenics to develop companion imaging agents for an anti-cancer drug being developed by the Rockville, Md.-based biotech firm.

Under the deal announced today, ImaginAb will develop companion imaging agents for B7-H3, an immune regulator target for which MacroGenics is developing therapeutics. It also is developing a clinical imaging strategy based on a Macrogenics anti-CD3 antibody as a patient selection tool for ongoing clinical programs.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: transcriptome patterns of Zika-infected cells, updated Comparative Toxicogenomics Database, and more.

BMJ study says that about half of former hematology-oncology regulators now work for industry.

Science should wish PhDs who leave academia well, a Nature editorial says.

New York-based doctors announce the birth of a baby boy whose parents underwent mitochondrial transfer therapy, New Scientist reports.